scPharmaceuticals Competitors and Similar CompaniesClear all
Oxurion's competitors and similar companies include Sorrento Therapeutics.
 Oxurion Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
| |
Founding Date | Founding Date 1991 | Founding Date 2006 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations Leuven, BE HQ Dublin 8, IE | Locations San Diego, US HQ San Diego, US |
Employees | Employees 785% increase | Employees 31019% decrease |
Valuation ($) | Valuation ($) 626.1 k | Valuation ($) 1.5 m |
Financial | ||
Revenue (est.) | Revenue (est.) €555k (FY, 2025) | Revenue (est.) $62.8m (FY, 2022) |
Net income | Net income (€3.7m) (FY, 2025) | Net income ($577.8m) (FY, 2022) |
Funding | ||
Total funding raised | Total funding raised $ 3.9m | Total funding raised $ 42.6m |
For sources of this data, please see the company profile
View Company Profiles
Sorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View company